Biotech

All Articles

Despite mixed market, an equity capital resurgence can be being available in Europe: PitchBook

.While the biotech financial investment scene in Europe has decreased somewhat following a COVID-19 ...

8 months after a $213M fundraise, gene editor Tome helps make cuts

.After increasing $213 million in 2023-- among the year's largest exclusive biotech shots-- Volume B...

BioMarin develops director crew along with biotech veterinarians-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our summary of substantial leadership hirings, shootings...

Biopharma Q2 VC hit highest level given that '22, while M&ampA slowed

.Venture capital backing into biopharma cheered $9.2 billion around 215 handle the 2nd fourth of thi...

Bicara, Zenas seek IPOs to drive late-phase resources towards market

.Bicara Therapies and Zenas Biopharma have delivered new catalyst to the IPO market with filings tha...

Genentech to shut cancer cells immunology analysis division

.Genentech will close its own cancer immunology analysis division, as well as unit mind and also ren...

Kezar goes down strong growth yet to prove its own well worth in phase 1 trial

.Kezar Life Sciences is falling its own unpromising period 1 strong growth medicine as the biotech g...

Acelyrin loses izokibep, dismisses 3rd of staff

.In spite of izokibep keeping its newfound winning touch in the clinic, Acelyrin is no longer focusi...

Rivus' stage 2 obesity-related cardiac arrest test strikes endpoint

.Rivus Pharmaceuticals has plumped up the prospects of its fat-busting, muscle-sparing medicine cand...

Ovid standstills preclinical work, IV course after soticlestat fall short

.Ovid Therapeutics currently showed last month that it was trimming back its own headcount as the fi...